Other Events ·
Nasdaq notifies Milestone Pharmaceuticals of non-compliance with the $1.00 minimum bid price
MISTMilestone Pharmaceuticals Inc.
On October 23, 2026, Nasdaq notified Milestone Pharmaceuticals Inc. that its common shares failed to meet the continued listing requirement for a minimum bid price of $1.00 per share over the previous 30 consecutive business days. The company has an 180-day compliance period until April 21, 2027, to restore compliance by maintaining a closing price of at least $1.00 for ten consecutive business days. Failure to regain compliance may result in delisting from the Nasdaq Global Select Market or a transfer to the Nasdaq Capital Market, potentially requiring a reverse stock split. Milestone Pharmaceuticals Inc. operates in the biopharmaceutical industry.